Funding for this research was provided by:
U.S. Department of Defense (PC190189)
National Cancer Institute (CA111412, CA197292)
Article History
Accepted: 18 July 2021
First Online: 29 July 2021
Declarations
:
: This work was supported, in part, by US Department of Defense PC190189, NCI P01 CA111412 and R35 CA197292.
: Dr. Felices and Dr. Miller receive consulting honoraria, royalties and/or own stock from GT Biopharma, who licenses the TriKE<sup>TM</sup> platform from the University of Minnesota. These interests have been reviewed and managed by the University of Minnesota in accordance with its conflict-of-interest policy.
: Not applicable
: Not applicable
: SKP wrote and edited manuscript; JSM and MF supervised, reviewed, wrote, and organized manuscript.
: Not applicable.